SCHEMBL6330529

SCHEMBL6330529

CC(C)(C)N(O[Si](C)(C)C(C)(C)C)c1ccc(C(=O)Nc2nccs2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.55
NPC1 O15118 7/20 0.55
SMN1; SMN2 Q16637 4/20 0.55
AGER Q15109 1/20 0.55
ADORA2A P29274 5/20 0.55
HSD17B10 Q99714 2/20 0.53
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
LMNA P02545 3/20 0.52
RECQL P46063 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
MAPK1 P28482 3/20 0.51
ALDH1A1 P00352 2/20 0.51
GBA1 P04062 1/20 0.51
HPGD P15428 1/20 0.51
TSHR P16473 1/20 0.51
MAPK10 P53779 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
SCD O00767 1/20 0.50
TP53 P04637 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6328478 0.84 RAB9A (0.61) RAB9ANPC1SMN1; SMN2AGERADORA2A
SCHEMBL6327447 0.81 RAB9A (0.62) RAB9ANPC1SMN1; SMN2AGERADORA2A
SCHEMBL6328266 0.80 NPC1 (0.64) RAB9ANPC1SMN1; SMN2AGERADORA2A
SCHEMBL6332343 0.79 NPC1 (0.57) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL16378731 0.75 RAB9A (0.73) RAB9ANPC1SMN1; SMN2AGERADORA2A
SCHEMBL10440021 0.75 HPGD (0.43) RAB9ANPC1LMNAALDH1A1HPGD
SCHEMBL6330536 0.74 KMT2A (0.57) RAB9ANPC1SMN1; SMN2HSD17B10MEN1
SCHEMBL6330278 0.74 HPGD (0.41) NPC1SMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL4287864 0.73 ADORA2A (0.63) RAB9ANPC1SMN1; SMN2AGERADORA2A
SCHEMBL4295195 0.73 RAB9A (0.76) RAB9ANPC1SMN1; SMN2AGERADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6949654-B2 N-alkyl-N-phenylhydroxylamine compounds containing metal chelating groups, their preparation and their therapeutic uses SAM-SUNG ELECTRONICS CO., LTD. (KR) 2005-09-27 US disclosed
US-20030225087-A1 N-alkyl-N-phenylhydroxylamine compounds containing metal chelating groups, their preparation and their therapeutic uses SAM-SUNG ELECTRONICS CO., LTD. (KR) 2003-12-04 US disclosed
WO-2003010153-A1 N-ALKYL-N-PHENYLHYDROXYLAMINE COMPOUNDS CONTAINING METAL CHELATING GROUPS, THEIR PREPARATION AND THEIR THERAPEUTIC USES SAMSUNG ELECTRONICS CO. LTD. (KR) 2003-02-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225087-A1 N-alkyl-N-phenylhydroxylamine compounds containing metal chelating groups, their preparation and their therapeutic uses SOD1, LPO, BAD RAB9A 539/4885NPC1 322/4885SMN1; SMN2 244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.